Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 50

References for PMC Articles for PubMed (Select 20859453)

1.

Tumour necrosis factor inhibitor-related lupus: safety of switching agents.

Luong JM, Tan BT, Buchanan RR, Schachna L.

Clin Rheumatol. 2010 May;29(5):551-3. doi: 10.1007/s10067-009-1365-y. Epub 2010 Feb 2.

PMID:
20119843
2.

Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study.

Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, Fleisher T, Balow JE, Lipsky PE.

Arthritis Rheum. 2010 Feb;62(2):542-52. doi: 10.1002/art.27221.

3.

Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register.

Saad AA, Ashcroft DM, Watson KD, Symmons DP, Noyce PR, Hyrich KL; BSRBR.

Rheumatology (Oxford). 2010 Apr;49(4):697-705. doi: 10.1093/rheumatology/kep423. Epub 2010 Jan 7.

4.

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.

Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG.

Arthritis Rheum. 2010 Jan;62(1):222-33. doi: 10.1002/art.27233.

5.

Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study.

Jacobi AM, Huang W, Wang T, Freimuth W, Sanz I, Furie R, Mackay M, Aranow C, Diamond B, Davidson A.

Arthritis Rheum. 2010 Jan;62(1):201-10. doi: 10.1002/art.27189.

6.

Pseudoviral immunity - a novel concept for lupus.

Anders HJ.

Trends Mol Med. 2009 Dec;15(12):553-61. doi: 10.1016/j.molmed.2009.10.004. Epub 2009 Nov 4.

PMID:
19896418
7.

Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases.

Farge D, Labopin M, Tyndall A, Fassas A, Mancardi GL, Van Laar J, Ouyang J, Kozak T, Moore J, Kötter I, Chesnel V, Marmont A, Gratwohl A, Saccardi R.

Haematologica. 2010 Feb;95(2):284-92. doi: 10.3324/haematol.2009.013458. Epub 2009 Sep 22.

8.

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.

Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, Petri MA, Ginzler EM, Chatham WW, McCune WJ, Fernandez V, Chevrier MR, Zhong ZJ, Freimuth WW.

Arthritis Rheum. 2009 Sep 15;61(9):1168-78. doi: 10.1002/art.24699.

9.

Abetimus sodium: a medication for the prevention of lupus nephritis flares.

Horowitz DM, Furie RA.

Expert Opin Pharmacother. 2009 Jun;10(9):1501-7. doi: 10.1517/14656560902946419. Review.

PMID:
19505217
10.

Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans.

Sun L, Akiyama K, Zhang H, Yamaza T, Hou Y, Zhao S, Xu T, Le A, Shi S.

Stem Cells. 2009 Jun;27(6):1421-32. doi: 10.1002/stem.68.

11.

Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus.

Yao Y, Richman L, Higgs BW, Morehouse CA, de los Reyes M, Brohawn P, Zhang J, White B, Coyle AJ, Kiener PA, Jallal B.

Arthritis Rheum. 2009 Jun;60(6):1785-96. doi: 10.1002/art.24557.

PMID:
19479852
12.

Etanercept-associated SLE with lupus nephritis.

Neradová A, Stam F, van den Berg JG, Bax WA.

Lupus. 2009 Jun;18(7):667-8. doi: 10.1177/0961203308100560. No abstract available.

PMID:
19433471
13.

Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.

Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sánchez-Guerrero J, Solomons N, Wofsy D; Aspreva Lupus Management Study Group.

J Am Soc Nephrol. 2009 May;20(5):1103-12. doi: 10.1681/ASN.2008101028. Epub 2009 Apr 15.

14.

Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): immunomodulation of gene expression.

Sthoeger ZM, Sharabi A, Molad Y, Asher I, Zinger H, Dayan M, Mozes E.

J Autoimmun. 2009 Aug;33(1):77-82. doi: 10.1016/j.jaut.2009.03.009. Epub 2009 Apr 5.

PMID:
19346102
15.

A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients.

Lu TY, Ng KP, Cambridge G, Leandro MJ, Edwards JC, Ehrenstein M, Isenberg DA.

Arthritis Rheum. 2009 Apr 15;61(4):482-7. doi: 10.1002/art.24341.

PMID:
19333973
16.

Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy.

Austin HA 3rd, Illei GG, Braun MJ, Balow JE.

J Am Soc Nephrol. 2009 Apr;20(4):901-11. doi: 10.1681/ASN.2008060665. Epub 2009 Mar 18.

17.

Monoclonal antibodies in the treatment of systemic lupus erythematosus.

Robak E, Robak T.

Curr Drug Targets. 2009 Jan;10(1):26-37. Review.

PMID:
19149533
18.

TNF inhibition in SLE: where do we stand?

Aringer M, Smolen JS.

Lupus. 2009 Jan;18(1):5-8. doi: 10.1177/0961203308098190. No abstract available.

PMID:
19074162
19.

The Tie2 receptor antagonist angiopoietin 2 facilitates vascular inflammation in systemic lupus erythematosus.

Kümpers P, David S, Haubitz M, Hellpap J, Horn R, Bröcker V, Schiffer M, Haller H, Witte T.

Ann Rheum Dis. 2009 Oct;68(10):1638-43. doi: 10.1136/ard.2008.094664. Epub 2008 Oct 17.

PMID:
18930996
20.

Cyclosporine (CsA) in lupus nephritis: assessing the evidence.

Moroni G, Doria A, Ponticelli C.

Nephrol Dial Transplant. 2009 Jan;24(1):15-20. doi: 10.1093/ndt/gfn565. Epub 2008 Oct 13. Review. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk